#Orforglipron

Orforglipron is Eli Lilly's small-molecule, non-peptide GLP-1 receptor agonist — the first true oral GLP-1 cleared for obesity, branded as Foundayo. Unlike semaglutide and tirzepatide, orforglipron requires no fatty-acid modification and no peptide-stabilizing matrix to survive the gut. The molecule is primarily hepatically metabolized; the label warns against use in severe hepatic impairment, but mild-to-moderate liver impairment is allowed at the standard dose.

The ACHIEVE Phase 3 program covered type-2 diabetes (ACHIEVE-1, ACHIEVE-2), obesity (ACHIEVE-3, ACHIEVE-4), and adjacent indications. The FDA approved the obesity indication in April 2026. Indirect comparisons against oral semaglutide and oral Wegovy have been mixed: orforglipron leads on HbA1c, oral semaglutide may lead on weight loss. By the April 30 Q1 2026 call, roughly 20,000 patients were on the drug, more than 8,000 prescribers had written it, and Lilly confirmed commercial access at two of the three largest US PBMs effective mid-May. On May 4, an FAERS hepatic-failure case logged April 30 surfaced publicly — Lilly's Global Patient Safety team called the event 'not reasonably related to Foundayo,' and the company released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program.

The small-molecule approach carries pricing and manufacturing implications the peptide GLP-1 economy does not — CDMO capacity stops being the bottleneck, and small-molecule generics will eventually follow a different cost curve. Stories here cover trial readouts, post-launch tracking, and competing oral programs.